Table 1

Baseline characteristics

All (n=30)TN (n=16)HR+ (n=14)
Clinical characteristics
Age, median (range)51 (27–68)54.5 (27–68)49 (36–68)
Race, % (n)
 White83% (25)88% (14)79% (11)
 Black10% (3)6% (1)14% (2)
 Unknown7% (2)6% (1)7% (1)
Ethnicity, % (n)
 Non-Hispanic93% (28)94% (15)93% (13)
 Hispanic7% (2)6% (1)7% (1)
ECOG PS, % (n)
 057% (17)56% (9)57% (8)
 140% (12)38% (6)43% (6)
 23% (1)6% (1)0% (0)
Visceral disease93% (28)88% (14)100% (14)
Prior therapies for MBC
Total prior therapies, median (range)1 (0–6)1 (0–6)2 (0–4)
Endocrine therapy, median (range)0 (0–4)N/A1 (0–3)
Chemotherapy, median (range)1 (0–5)1 (0–5)0 (0–2)
First line for MBC, % (n)17% (7)31% (5)7% (1)
  • ECOG, Eastern Cooperative Oncology Group; HR+, hormone receptor-positive endocrine-refractory ; MBC, metastatic breast cancer ; N/A, not available; PS, performance status; TN, triple negative .